Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
PULM Pulmatrix, Inc. daily Stock Chart
PULM [NASD]
Pulmatrix, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.01 Insider Own- Shs Outstand24.38M Perf Week-4.69%
Market Cap31.76M Forward P/E- EPS next Y-1.44 Insider Trans- Shs Float- Perf Month-8.96%
Income-20.10M PEG- EPS next Q-0.40 Inst Own21.60% Short Float- Perf Quarter-25.15%
Sales10.70M P/S2.97 EPS this Y75.30% Inst Trans90.89% Short Ratio0.36 Perf Half Y-15.28%
Book/sh0.57 P/B2.14 EPS next Y-6.70% ROA-39.90% Target Price- Perf Year40.23%
Cash/sh1.05 P/C1.16 EPS next 5Y- ROE-115.60% 52W Range0.61 - 2.06 Perf YTD41.86%
Dividend- P/FCF- EPS past 5Y48.70% ROI- 52W High-45.99% Beta1.68
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low81.88% ATR0.10
Employees22 Current Ratio2.00 Sales Q/Q-27.10% Oper. Margin- RSI (14)28.39 Volatility5.98% 6.90%
OptionableNo Debt/Eq0.00 EPS Q/Q88.20% Profit Margin- Rel Volume1.87 Prev Close1.22
ShortableYes LT Debt/Eq0.00 EarningsAug 17 BMO Payout- Avg Volume953.76K Price1.11
Recom- SMA20-15.23% SMA50-28.02% SMA200-17.67% Volume1,068,753 Change-9.02%
Feb-09-18Initiated H.C. Wainwright Buy $5
Aug-07-20 09:00AM  
Pulmatrix Reports Q2 2020 Results and Business Updates
PR Newswire
Jul-08-20 08:30AM  
Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles
PR Newswire +6.04%
Jun-26-20 09:00AM  
Pulmatrix Announces Changes to Board of Directors
PR Newswire
May-27-20 09:00AM  
Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually
PR Newswire
May-14-20 09:00AM  
Pulmatrix Reports Q1 2020 Results
PR Newswire
Apr-29-20 10:02AM  
Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks
TipRanks +8.21%
Apr-16-20 05:25PM  
Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
PR Newswire +5.99%
08:30AM  
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19
PR Newswire
Mar-26-20 09:00AM  
Pulmatrix Reports 2019 Financial Results and Provides Business Update
PR Newswire -11.57%
Jan-31-20 07:20AM  
The Wining Sector & Its Top Stocks in Virus-Infected January
Zacks
Jan-30-20 08:00AM  
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
PR Newswire
Jan-16-20 12:05PM  
Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR Newswire
Jan-06-20 08:58AM  
Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies
PR Newswire +5.30%
Jan-03-20 09:55AM  
Pulmatrix Surges on License Agreement With Johnson & Johnson
Zacks -6.79%
Jan-02-20 08:51AM  
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
PR Newswire +88.37%
Nov-04-19 09:15AM  
Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors
PR Newswire
Nov-01-19 09:00AM  
Pulmatrix Reports Q3 2019 Results
PR Newswire
Sep-18-19 09:30AM  
Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma
PR Newswire
Aug-19-19 09:25AM  
Pulmatrix Receives US Patent Covering iSPERSE Formulations for Pulmazole Program
PR Newswire
Aug-05-19 09:00AM  
Pulmatrix Reports Q2 2019 Results
PR Newswire
Jun-07-19 10:25AM  
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
Zacks
Jun-06-19 06:42AM  
Bet on 5 Top Stocks With Rising P/E
Zacks
May-16-19 09:10AM  
Pulmatrix Announces Leadership Change
PR Newswire
May-15-19 09:00AM  
Pulmatrix Reports Q1 2019 Results
PR Newswire
Apr-15-19 09:00AM  
Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole
PR Newswire
Apr-08-19 04:29PM  
Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering
PR Newswire
Apr-03-19 09:30PM  
Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering
PR Newswire -22.77%
Apr-01-19 05:33PM  
Pulmatrix News: PULM Stock Skyrockets on Asthma Drug Deal
InvestorPlace +81.89%
02:34PM  
Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatment
MarketWatch
09:00AM  
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
PR Newswire
Mar-14-19 09:45AM  
Pulmatrix to Participate in Upcoming Investor Conferences
PR Newswire +19.01%
Mar-12-19 12:22PM  
Pulmatrix Regains NASDAQ Compliance
PR Newswire
Mar-08-19 01:00PM  
These Four Tech Stocks Could Set The Pace On Friday
ACCESSWIRE +39.37%
Feb-19-19 09:00AM  
Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline
PR Newswire -6.84%
Feb-12-19 09:30AM  
Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs
PR Newswire -6.93%
Feb-08-19 07:00AM  
Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
PR Newswire -32.84%
Feb-07-19 09:00AM  
Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
PR Newswire -9.46%
Feb-06-19 12:15PM  
4 Biotech Stocks Making Moves on Wednesday (2/6/19)
ACCESSWIRE
09:00AM  
Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1
PR Newswire
Feb-05-19 12:45PM  
Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split
PR Newswire -9.37%
11:14AM  
Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire
Jan-31-19 01:24PM  
Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire -28.29%
Jan-30-19 09:52PM  
Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire
04:01PM  
Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire
Jan-28-19 11:27PM  
Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire -9.62%
04:18PM  
Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire
Nov-29-18 05:00AM  
Pulmatrix Announces $3.0 Million Registered Direct Offering
PR Newswire
Nov-21-18 09:30AM  
Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole
PR Newswire -5.73%
Nov-15-18 09:30AM  
Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology
PR Newswire -7.02%
Nov-14-18 04:30PM  
Pulmatrix Reports Q3 2018 Results
PR Newswire
Sep-18-18 11:45AM  
Who Owns Most Of Pulmatrix Inc (NASDAQ:PULM)?
Simply Wall St. +8.13%
Sep-17-18 09:35AM  
Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress
PR Newswire +5.36%
Aug-28-18 10:00AM  
Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018
PR Newswire +5.99%
Aug-03-18 09:00AM  
Pulmatrix Reports Q2 2018 Results
PR Newswire -11.49%
Jul-23-18 10:13AM  
Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development
PR Newswire
Jul-20-18 07:20AM  
Free Technical Research on Riot Blockchain and Three More Biotech Equities
ACCESSWIRE
Jul-17-18 09:00AM  
Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole
PR Newswire
Jun-25-18 08:30AM  
Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole
PR Newswire
Jun-13-18 09:35AM  
Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients
PR Newswire +6.48%
Jun-07-18 09:30AM  
Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders
PR Newswire +9.73%
Jun-04-18 07:40AM  
Wired News - Madrigal Pharma Reported Encouraging Top-line Data at 36 Weeks from Phase-2 Clinical Trial of MGL-3196 in Patients with NASH
ACCESSWIRE
07:20AM  
Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities
ACCESSWIRE
May-25-18 12:49PM  
Interested In Pulmatrix Inc (NASDAQ:PULM)? Heres How It Performed Recently
Simply Wall St.
May-17-18 09:35AM  
Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego
PR Newswire
May-11-18 09:00AM  
Pulmatrix Reports Q1 2018 Results
PR Newswire
Mar-29-18 12:02AM  
Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering
PR Newswire -30.28%
Mar-13-18 04:42PM  
Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline
PR Newswire
Mar-09-18 09:46AM  
Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?
Simply Wall St.
Feb-12-18 09:35AM  
Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole
PR Newswire
Jan-29-18 08:00AM  
Todays Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix
ACCESSWIRE
Jan-28-18 11:01PM  
Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?
Simply Wall St.
Jan-25-18 10:30AM  
PULM: MHRA Authorizes CTA; Patient Screening Commences!
Zacks Small Cap Research +15.07%
Jan-24-18 12:00PM  
Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018
PR Newswire
Jan-22-18 10:25AM  
Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole
PR Newswire
Dec-19-17 11:45AM  
How Pulmatrix Incs (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?
Simply Wall St.
Dec-04-17 05:10PM  
Pulmatrix Inc (PULM): Time For A Financial Health Check
Simply Wall St.
Nov-29-17 08:47AM  
Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Capital Cube
Nov-14-17 01:00PM  
PULM: Business And Financial Update For Third Quarter 2017
Zacks Small Cap Research
Nov-09-17 04:30PM  
Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials
PR Newswire
Oct-31-17 11:00AM  
Pulmatrix Presents at the North American Cystic Fibrosis Conference
PR Newswire
Oct-30-17 09:45AM  
Pulmatrix Appoints Dr. James Roach as Chief Medical Officer
PR Newswire
Oct-24-17 10:00AM  
Pulmatrix: Company to Watch in Lung Disease Market
ACCESSWIRE
Oct-11-17 02:14PM  
Is It Time To Buy Pulmatrix Inc (PULM)?
Simply Wall St.
Oct-03-17 09:45AM  
Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
PR Newswire
Sep-27-17 08:10AM  
Today's Research Reports on Trending Tickers: Opko Health and Pulmatrix
ACCESSWIRE
Sep-21-17 09:50AM  
Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017
PR Newswire
Sep-20-17 09:40AM  
Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug
PR Newswire
Sep-19-17 05:57PM  
Is It The Right Time To Buy Pulmatrix Inc (PULM)?
Simply Wall St.
02:04PM  
CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months
GlobeNewswire
11:00AM  
PULM: Influx Of Grant And Partnership Deal- Signs Of Growing Confidence In Pulmatrix
Zacks Small Cap Research
Sep-08-17 09:30AM  
Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 11, 2017
PR Newswire
Sep-06-17 08:32AM  
Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc
PR Newswire
08:00AM  
Today's Research Reports on Trending Tickers: Pulmatrix Inc. and Portola Pharmaceuticals Inc.
ACCESSWIRE
04:37AM  
Vectura Announces Major New Tiotropium Bromide PI Development Programme Accelerated Through Licensing of Pulmatrix Technology
Benzinga
Sep-05-17 10:00AM  
Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections
PR Newswire
Aug-04-17 08:55AM  
Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials
PR Newswire
Aug-03-17 10:30AM  
PULM: Pulmatrix Broadens Its Pulmonary Portfolio With Addition of In-Licensed Janssen Compound for COPD
Zacks Small Cap Research
Jul-31-17 10:00AM  
Pulmatrix Strengthens Its Financials and Improves Outlook
ACCESSWIRE
Jun-26-17 10:00AM  
Innovative Pulmatrix Drug Offers New Hope for Fighting Fungal Lung Infections
Accesswire
Jun-15-17 12:13PM  
Amit D. Munshi Joins Pulmatrix's Board of Directors
PR Newswire
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a research collaboration with Nocion Therapeutics Inc. to explore technologies that enable and improve inhaled drug delivery. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
open in yahoo | open in reuters | open in google